WO1990006110A1 - Treatment of obesity - Google Patents
Treatment of obesity Download PDFInfo
- Publication number
- WO1990006110A1 WO1990006110A1 PCT/GB1989/001383 GB8901383W WO9006110A1 WO 1990006110 A1 WO1990006110 A1 WO 1990006110A1 GB 8901383 W GB8901383 W GB 8901383W WO 9006110 A1 WO9006110 A1 WO 9006110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclobutyl
- chlorophenyl
- obesity
- treatment
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- This invention relates to the medical treatment of obesity.
- a method of treating obesity in which a therapeutically effective amount of ,N-dimethyl-1 [1- (4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydro ⁇ chloride is administered in conjunction with a pharmaceutically acceptable diluent or carrier.
- a particularly preferred form of this compound is ,N-dimethyl-1-[1 -( ⁇ -chlorophenyl)cyclobutyl]-3- methylbutylamine hydrochloride monohydrate (sibutramine hydrochloride) which is described in European Patent Application 230742.
- the therapeutically active compound may be administered in any of the known pharmaceutical dosage forms for example solid dosage forms such as tablets or capsules or liquid dosage forms for example those forms intended for oral or parenteral administration.
- the amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound to be administered will be in the range 0.1 to 50 mg preferably 1 to 30'mg per day given in one or more doses.
- sibutramine hydrochloride The ability of sibutramine hydrochloride to cause weight reduction in humans has been demonstrated by the following trials.
- a first group (Group 1) of 15 subjects were given 2.5 mg sibutramine hydrochloride per day for the first two weeks of the trial, followed by 5 mg sibutramine hydrochloride per day for the remaining four weeks of the trial.
- the second group (Group 2) of 15 subjects were given 5 mg sibutramine hydrochloride per day for the first two weeks of the trial, followed by 10 mg sibutramine hydrochloride per day for the remaining four weeks of the trial.
- the third group (Group 3) of 9 subjects were given a placebo containing no sibutramine hydrochloride.
- the subjects were treated with a single dose of sibutramine hydrochloride or placebo taken each morning of the trial.
- the weight of each subject was taken at the commencement of treatment and after six weeks.
- the weight of each, subject (in kg) at the start and the change in weight (in kg) over the six week trial period is given in Table 1 below.
- a first group (Group 1) of 26 subjects were treated with 10 mg of sibutramine hydrochloride per day for the first two weeks of the trial and then with 20 mg of sibutramine hydrochloride per day for a further period of four weeks.
- the second group (Group 2) were given a placebo containing no sibutramine hydrochloride every day throughout the trial.
- the subjects were treated with a single dose of sibutramine hydrochoride or placebo taken each morning of the trial.
- the weight of each subject was taken at the commencement of the trial and after six weeks.
- the weight of each subject (in kg) at the start and the change in weight (in kg) over the six week period are given below in Table 2.
- a first group (Group 1) of 14 subjects were treated with 15 mg of sibutramine hydrochloride per day for the first two weeks of the trial and then with 30 mg of sibutramine hydrochloride for a further period of four weeks.
- the second group (Group 2) were given a placebo containing no sibutramine hydrochloride every day throughout the trial.
- the subjects were treated with a single dose of sibutramine hydrochloride or placebo taken each morning of the trial.
- the weight of each subject was taken at the commencement of the trial and after six weeks.
- the weight of each subject (in kg) at the start of the trial and the change in weight (in kg) over the six week period are given below in Table 3.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT89912801T ATE94385T1 (de) | 1988-11-29 | 1989-11-21 | Behandlung von obesitas. |
KR1019900701628A KR0164435B1 (ko) | 1988-11-29 | 1989-11-21 | 비만증 치료용 약제학적 조성물 |
JP2500580A JPH06102622B2 (ja) | 1988-11-29 | 1989-11-21 | 肥満の治療 |
DK199001776A DK175587B1 (da) | 1988-11-29 | 1990-07-26 | Behandling af fedme |
HK98105187A HK1006002A1 (en) | 1988-11-29 | 1998-06-11 | Treatment of obesity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27724088A | 1988-11-29 | 1988-11-29 | |
US277,240 | 1988-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990006110A1 true WO1990006110A1 (en) | 1990-06-14 |
Family
ID=23060006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1989/001383 WO1990006110A1 (en) | 1988-11-29 | 1989-11-21 | Treatment of obesity |
Country Status (16)
Country | Link |
---|---|
US (1) | US5436272A (da) |
EP (1) | EP0397831B1 (da) |
JP (1) | JPH06102622B2 (da) |
KR (1) | KR0164435B1 (da) |
AU (1) | AU633529B2 (da) |
CA (1) | CA2003524C (da) |
DE (2) | DE19975039I2 (da) |
DK (1) | DK175587B1 (da) |
HK (1) | HK1006002A1 (da) |
IE (1) | IE61928B1 (da) |
IL (1) | IL92406A (da) |
LU (1) | LU90866I2 (da) |
NL (1) | NL300066I2 (da) |
PH (1) | PH26677A (da) |
WO (1) | WO1990006110A1 (da) |
ZA (1) | ZA899058B (da) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5068440A (en) * | 1985-12-17 | 1991-11-26 | Boots Company, Plc | Process for the manufacture of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate |
WO1994000114A1 (en) * | 1992-06-23 | 1994-01-06 | Sepracor Inc. | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
US5459164A (en) * | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
WO1996038134A1 (de) * | 1995-05-29 | 1996-12-05 | Knoll Ag | Verwendung arylsubstituierter cyclobutylalkylamine zur behandlung der fettleibigkeit |
WO1998013033A1 (en) * | 1996-09-25 | 1998-04-02 | Knoll Aktiengesellschaft | Medical treatment |
AU721924B2 (en) * | 1992-06-23 | 2000-07-20 | Sepracor, Inc. | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
US6174925B1 (en) | 1996-09-21 | 2001-01-16 | Knoll Aktiengesellschaft | Use of sibutramine analogues to prevent the development of diabetes |
US6187820B1 (en) | 1996-09-25 | 2001-02-13 | Knoll Aktiengesellschaft | Medical treatment to improve lipid levels |
WO2001034140A1 (en) * | 1999-11-06 | 2001-05-17 | Abbott Gmbh & Co. Kg | Pharmaceutical formulation |
WO2001062341A2 (en) * | 2000-02-22 | 2001-08-30 | Knoll Gmbh | Combination product for the treatment of obesity |
US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
EP1162966A1 (en) * | 1999-03-19 | 2001-12-19 | Knoll Pharmaceutical Company | Weight loss after pregnancy |
EP1165060A1 (en) * | 1999-03-19 | 2002-01-02 | Knoll GmbH | Treatment of gallstones |
EP1169029A1 (en) * | 1999-03-19 | 2002-01-09 | Knoll GmbH | Method of treating sleep apnoea |
US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
US6365632B1 (en) | 1999-03-19 | 2002-04-02 | Knoll Pharmaceuticals Company | Treatment of orthostatic hypotension |
US6372798B1 (en) | 1999-03-19 | 2002-04-16 | Knoll Pharmaceutical Company | Treatment of hyperactivity disorders |
US6376551B1 (en) | 1999-03-19 | 2002-04-23 | Knoll Pharmaceutical Company | Treatment of chronic fatigue syndrome |
US6376554B1 (en) | 1999-03-19 | 2002-04-23 | Knoll Pharmaceutical Company | Method of treating sexual dysfunction |
US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
US6403650B1 (en) | 1999-03-19 | 2002-06-11 | Knoll Pharmaceutical Company | Treatment of pulmonary hypertension |
US6433020B1 (en) | 1999-03-19 | 2002-08-13 | Knoll Pharmaceutical Company | Treatment of cardiovascular disease |
US6441046B1 (en) | 1999-03-19 | 2002-08-27 | Abbott Gmbh & Co. Kg | Control of metabolism |
US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
US6610887B2 (en) | 2001-04-13 | 2003-08-26 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
US6803387B1 (en) | 1999-03-19 | 2004-10-12 | Abbott Gmbh & Co. Kg | Treatment of neuropathic pain or fibromyalgia |
US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
US7148258B2 (en) | 2000-10-04 | 2006-12-12 | Aventis Pharma S.A. | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
BG65170B1 (bg) * | 1999-03-17 | 2007-05-31 | Knoll Gmbh | Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето |
EP1328269B2 (fr) † | 2000-10-04 | 2008-07-30 | Aventis Pharma S.A. | Association d'un antagoniste du recepteur cb1 et de la sibutramine pour le traitement de l'obesite |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9727131D0 (en) | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
US6046242A (en) * | 1998-11-27 | 2000-04-04 | Basf Aktiengesellschaft | Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence |
US6696495B2 (en) | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
KR100432825B1 (ko) * | 1999-03-19 | 2004-05-24 | 애보트 게엠베하 운트 콤파니 카게 | 식이 장애 치료용 약제학적 조성물 |
US6552087B1 (en) | 1999-03-19 | 2003-04-22 | Abbott Gmbh & Co. Kg | Therapeutic agent comprising (+)-sibutramine |
NZ514016A (en) * | 1999-03-19 | 2001-09-28 | Knoll Gmbh | Treatment of osteoarthritis |
JP2002539251A (ja) * | 1999-03-19 | 2002-11-19 | クノール・ゲー・エム・ベー・ハー | 治療薬に伴う体重増加を調節する方法 |
US6245782B1 (en) | 1999-05-17 | 2001-06-12 | Heartdrug Research L.L.C. | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
AU2001282913A1 (en) * | 2000-09-08 | 2002-03-22 | Eli Lilly And Company | A method of treating weight gain associated with atypical antipsychotic use |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
NZ534757A (en) * | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20050131074A1 (en) * | 2003-08-04 | 2005-06-16 | Beckman Kristen M. | Methods for treating metabolic syndrome |
CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
JP2008526836A (ja) | 2005-01-06 | 2008-07-24 | シージェー チェイルジェダン コーポレーション | シブトラミンの無機酸塩 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
RU2417985C2 (ru) | 2005-05-30 | 2011-05-10 | Баниу Фармасьютикал Ко., Лтд. | Новые производные пиперидина |
US20100216758A1 (en) | 2005-08-10 | 2010-08-26 | Makoto Ando | Pyridone Compounds |
JPWO2007024004A1 (ja) | 2005-08-24 | 2009-03-05 | 萬有製薬株式会社 | フェニルピリドン誘導体 |
EP1939194A4 (en) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE |
EP1938811A4 (en) * | 2005-09-22 | 2008-12-17 | Eisai R&D Man Co Ltd | MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
JP2009512715A (ja) | 2005-10-21 | 2009-03-26 | ノバルティス アクチエンゲゼルシャフト | レニン阻害剤と抗異脂肪血症剤および/または抗肥満症剤の組み合わせ |
CA2627139A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
EP1953165B1 (en) | 2005-11-10 | 2012-02-01 | Msd K.K. | Aza-substituted spiro derivative |
RU2477634C2 (ru) * | 2006-06-16 | 2013-03-20 | Теракос, Инк. | Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов |
US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
EP2063890A1 (en) | 2006-09-07 | 2009-06-03 | Nycomed GmbH | Combination treatment for diabetes mellitus |
EP2066329B1 (en) | 2006-09-15 | 2017-09-06 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cyclobutylmethylamines |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
CA2664358A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diarylketimine derivative |
KR20090127904A (ko) * | 2007-04-09 | 2009-12-14 | 싸이도우스 엘엘씨. | 스타틴과 항비만제의 복합물 |
US20080249156A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
MX2009013354A (es) | 2007-06-04 | 2010-07-06 | Univ Ben Gurion | Compuestos de triarilo y composiciones que los contienen. |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Msd株式会社 | 5員−5員又は5員−6員縮環シクロアルキルアミン誘導体 |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
WO2010065889A2 (en) * | 2008-12-06 | 2010-06-10 | Auspex Pharmaceutical | Cyclobutanemethanamine inhibitors of monomine reuptake |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2012003501A2 (en) | 2010-07-02 | 2012-01-05 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CN113388007A (zh) | 2013-06-05 | 2021-09-14 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10111880B2 (en) | 2013-11-05 | 2018-10-30 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
EP3186242B1 (en) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3526199B1 (en) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
CN113302189A (zh) | 2018-11-20 | 2021-08-24 | Tes制药有限责任公司 | α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988006444A1 (en) * | 1987-02-28 | 1988-09-07 | The Boots Company Plc | Arylcyclobutyl derivatives for treatment of parkinson's disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4443449A (en) * | 1981-04-06 | 1984-04-17 | The Boots Company Limited | Arylcyclobutylalkylamines and anti-depression composition and methods using same |
ZA821577B (en) * | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
GB2184122B (en) * | 1985-12-17 | 1989-10-18 | Boots Co Plc | N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate |
-
1989
- 1989-11-17 IE IE369089A patent/IE61928B1/en not_active IP Right Cessation
- 1989-11-21 KR KR1019900701628A patent/KR0164435B1/ko not_active IP Right Cessation
- 1989-11-21 DE DE1999175039 patent/DE19975039I2/de active Active
- 1989-11-21 JP JP2500580A patent/JPH06102622B2/ja not_active Expired - Lifetime
- 1989-11-21 AU AU46207/89A patent/AU633529B2/en not_active Expired
- 1989-11-21 EP EP89912801A patent/EP0397831B1/en not_active Expired - Lifetime
- 1989-11-21 DE DE89912801T patent/DE68909219T2/de not_active Expired - Lifetime
- 1989-11-21 WO PCT/GB1989/001383 patent/WO1990006110A1/en active IP Right Grant
- 1989-11-21 CA CA002003524A patent/CA2003524C/en not_active Expired - Lifetime
- 1989-11-22 IL IL9240689A patent/IL92406A/en active Protection Beyond IP Right Term
- 1989-11-24 PH PH39593A patent/PH26677A/en unknown
- 1989-11-28 ZA ZA899058A patent/ZA899058B/xx unknown
-
1990
- 1990-07-26 DK DK199001776A patent/DK175587B1/da not_active IP Right Cessation
-
1992
- 1992-10-15 US US07/962,175 patent/US5436272A/en not_active Expired - Lifetime
-
1998
- 1998-06-11 HK HK98105187A patent/HK1006002A1/xx not_active IP Right Cessation
-
2001
- 2001-10-04 NL NL300066C patent/NL300066I2/nl unknown
- 2001-12-18 LU LU90866C patent/LU90866I2/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988006444A1 (en) * | 1987-02-28 | 1988-09-07 | The Boots Company Plc | Arylcyclobutyl derivatives for treatment of parkinson's disease |
Non-Patent Citations (2)
Title |
---|
Lehrbuch der Pharmakologie und Toxikologie, ed. by Hermann Bader, Ed. Medizin Weinheim (DE) page 101 * |
Martindale The Extra Pharmacopoeia, 28th Edition, ed. by James E.F. Reynolds The Pharmaceutical Press, 1982 London (GB) page 65 * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5068440A (en) * | 1985-12-17 | 1991-11-26 | Boots Company, Plc | Process for the manufacture of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate |
WO1994000114A1 (en) * | 1992-06-23 | 1994-01-06 | Sepracor Inc. | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
AU721924B2 (en) * | 1992-06-23 | 2000-07-20 | Sepracor, Inc. | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
EP0814788A4 (en) * | 1994-02-03 | 1999-05-06 | Boots Pharma Inc | IMPROVEMENT OF GLUCOSE TOLERANCE |
EP0814788A1 (en) * | 1994-02-03 | 1998-01-07 | Boots Pharmaceuticals Inc. | Improving glucose tolerance |
US5942549A (en) * | 1994-02-03 | 1999-08-24 | Knoll Pharmaceutical Company | Improving glucose tolerance |
US5459164A (en) * | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
WO1996038134A1 (de) * | 1995-05-29 | 1996-12-05 | Knoll Ag | Verwendung arylsubstituierter cyclobutylalkylamine zur behandlung der fettleibigkeit |
US6127424A (en) * | 1995-05-29 | 2000-10-03 | Knoll Aktiengesesllschaft | Aryl-substituted cyclobutylalkylamines for treating obesity |
US6174925B1 (en) | 1996-09-21 | 2001-01-16 | Knoll Aktiengesellschaft | Use of sibutramine analogues to prevent the development of diabetes |
US6617360B1 (en) | 1996-09-21 | 2003-09-09 | Knoll Aktiengesellschaft | Medical treatment |
WO1998013033A1 (en) * | 1996-09-25 | 1998-04-02 | Knoll Aktiengesellschaft | Medical treatment |
AU722129B2 (en) * | 1996-09-25 | 2000-07-20 | Abbott Gmbh & Co. Kg | Medical treatment |
US6162831A (en) * | 1996-09-25 | 2000-12-19 | Knoll Aktiengesellschaft | Medical treatment to lower uric acid levels |
US6187820B1 (en) | 1996-09-25 | 2001-02-13 | Knoll Aktiengesellschaft | Medical treatment to improve lipid levels |
US6538034B2 (en) | 1998-08-24 | 2003-03-25 | Thomas P. Jerussi | Methods of treating or preventing weight gain, obesity, and related disorders |
US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
US7071234B2 (en) | 1998-08-24 | 2006-07-04 | Sepracor Inc. | Methods of treating or preventing erectile dysfunction |
US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
BG65170B1 (bg) * | 1999-03-17 | 2007-05-31 | Knoll Gmbh | Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето |
US6433020B1 (en) | 1999-03-19 | 2002-08-13 | Knoll Pharmaceutical Company | Treatment of cardiovascular disease |
EP1169029A4 (en) * | 1999-03-19 | 2004-01-21 | Abbott Gmbh & Co Kg | TREATMENT OF SLEEP APNEA |
US6365632B1 (en) | 1999-03-19 | 2002-04-02 | Knoll Pharmaceuticals Company | Treatment of orthostatic hypotension |
US6372798B1 (en) | 1999-03-19 | 2002-04-16 | Knoll Pharmaceutical Company | Treatment of hyperactivity disorders |
US6376551B1 (en) | 1999-03-19 | 2002-04-23 | Knoll Pharmaceutical Company | Treatment of chronic fatigue syndrome |
US6376554B1 (en) | 1999-03-19 | 2002-04-23 | Knoll Pharmaceutical Company | Method of treating sexual dysfunction |
EP1169029A1 (en) * | 1999-03-19 | 2002-01-09 | Knoll GmbH | Method of treating sleep apnoea |
US6403650B1 (en) | 1999-03-19 | 2002-06-11 | Knoll Pharmaceutical Company | Treatment of pulmonary hypertension |
EP1162966A4 (en) * | 1999-03-19 | 2002-06-12 | Knoll Gmbh | WEIGHT LOSS AFTER PREGNANCY |
EP1165060A4 (en) * | 1999-03-19 | 2002-06-12 | Knoll Gmbh | PROCESSING OF BILARIAL CALCULATIONS |
EP1165060A1 (en) * | 1999-03-19 | 2002-01-02 | Knoll GmbH | Treatment of gallstones |
US6441046B1 (en) | 1999-03-19 | 2002-08-27 | Abbott Gmbh & Co. Kg | Control of metabolism |
US6803387B1 (en) | 1999-03-19 | 2004-10-12 | Abbott Gmbh & Co. Kg | Treatment of neuropathic pain or fibromyalgia |
CZ298293B6 (cs) * | 1999-03-19 | 2007-08-15 | Abbott Gmbh & Co. Kg | Léčivo pro léčení poruch spánku |
EP1162966A1 (en) * | 1999-03-19 | 2001-12-19 | Knoll Pharmaceutical Company | Weight loss after pregnancy |
US6974837B2 (en) | 1999-08-11 | 2005-12-13 | Sepracor Inc. | Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors |
US6710087B2 (en) | 1999-08-11 | 2004-03-23 | Sepracor, Inc. | Methods of treating or preventing neuropathic pain using sibutramine metabolites |
US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
WO2001034140A1 (en) * | 1999-11-06 | 2001-05-17 | Abbott Gmbh & Co. Kg | Pharmaceutical formulation |
WO2001062341A2 (en) * | 2000-02-22 | 2001-08-30 | Knoll Gmbh | Combination product for the treatment of obesity |
WO2001062341A3 (en) * | 2000-02-22 | 2002-01-31 | Knoll Gmbh | Combination product for the treatment of obesity |
US7148258B2 (en) | 2000-10-04 | 2006-12-12 | Aventis Pharma S.A. | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
EP1328269B2 (fr) † | 2000-10-04 | 2008-07-30 | Aventis Pharma S.A. | Association d'un antagoniste du recepteur cb1 et de la sibutramine pour le traitement de l'obesite |
US6894189B2 (en) | 2001-04-13 | 2005-05-17 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
US6610887B2 (en) | 2001-04-13 | 2003-08-26 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
Also Published As
Publication number | Publication date |
---|---|
IL92406A (en) | 1995-07-31 |
EP0397831B1 (en) | 1993-09-15 |
NL300066I1 (nl) | 2001-12-01 |
DE68909219D1 (de) | 1993-10-21 |
EP0397831A1 (en) | 1990-11-22 |
NL300066I2 (nl) | 2002-06-03 |
CA2003524A1 (en) | 1990-05-29 |
AU4620789A (en) | 1990-06-26 |
JPH02503682A (ja) | 1990-11-01 |
DK175587B1 (da) | 2004-12-13 |
PH26677A (en) | 1992-09-15 |
DK177690D0 (da) | 1990-07-26 |
LU90866I2 (fr) | 2002-02-18 |
KR0164435B1 (ko) | 1999-01-15 |
DK177690A (da) | 1990-09-13 |
HK1006002A1 (en) | 1999-02-05 |
IE893690L (en) | 1990-05-29 |
IE61928B1 (en) | 1994-11-30 |
ZA899058B (en) | 1990-08-29 |
US5436272A (en) | 1995-07-25 |
AU633529B2 (en) | 1993-02-04 |
CA2003524C (en) | 1999-10-19 |
KR900701261A (ko) | 1990-12-01 |
DE68909219T2 (de) | 1994-01-13 |
JPH06102622B2 (ja) | 1994-12-14 |
DE19975039I2 (de) | 2000-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0397831B1 (en) | Treatment of obesity | |
Yahr et al. | Treatment of parkinsonism with levodopa | |
US4507323A (en) | Treatment of psychosexual dysfunctions | |
Bass et al. | Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis | |
EP0123469B1 (en) | Use of fluoxetine for the manufacture of an anti-anxiety agent | |
US4435449A (en) | Treatment of minimal brain dysfunction (MBD) | |
US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
US5708036A (en) | Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol | |
Gerolami et al. | Controlled trial of chenodeoxycholic therapy for radiolucent gallstones: A multicenter study | |
EP0171227B1 (en) | Use of propiophenone compound | |
WO1995022324A1 (en) | Treatment of migraine headaches and formulations | |
Kusner et al. | A study comparing the effectiveness of Ibuprofen (Motrin), Empirin with Codeine# 3, and Synalgos-DC for the relief of postendodontic pain | |
EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
JPH05201861A (ja) | デキストロメトルフアンの鎮咳効果の増強 | |
US4042698A (en) | Treatment of myasthenia gravis and oral medication therefor | |
Sapeika | Drugs in obesity | |
RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона | |
VASILE et al. | Alleviating gastrointestinal side effects of lithium carbonate by substituting lithium citrate | |
Ulm | Effect of budipine on parkinsonian tremor resistant to other antiparkinsonian medication | |
Shiwach et al. | Treatment of major depression complicated by bilateral foot drop and double incontinence with ECT | |
WO2023172148A1 (en) | Medication | |
Rab et al. | Double-blind multicentre isradipine dose-confirmation study in Pakistan | |
JPH07188002A (ja) | 鼻炎治療用組成物 | |
Martens | Double-blind randomized comparison of proglumetacin and naproxen sodium in the treatment of patients with ankle sprains | |
Hutchison et al. | Diuretic Therapy in the Treatment of Hypertension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1989912801 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019900701628 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1989912801 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1989912801 Country of ref document: EP |